PT  - JOURNAL ARTICLE
AU  - Edward C Keystone
TI  - Safety of biologic therapies--an update.
DP  - 2005 Mar 01
TA  - The Journal of Rheumatology
PG  - 8--12
VI  - 74
4099  - http://www.jrheum.org/content/74/8.short
4100  - http://www.jrheum.org/content/74/8.full
SO  - J Rheumatol2005 Mar 01; 74
AB  - Tumor necrosis factor (TNF) antagonists have set a new therapeutic standard for rheumatoid arthritis (RA). Agents including infliximab, etanercept, and adalimumab have demonstrated substantial improvement in signs and symptoms, disability, and quality of life, while significantly inhibiting joint damage in early and long-standing RA. Safety issues in concert with efficacy determine risk/benefit ratio and hence a position in the therapeutic algorithm. This brief review focuses on infection, congestive heart, and malignancy.